U.S. flag

An official website of the United States government

NM_201596.3(CACNB2):c.441T>C (p.Phe147=) AND Brugada syndrome 4

Germline classification:
Likely benign (1 submission)
Last evaluated:
Jul 15, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003621805.2

Allele description [Variation Report for NM_201596.3(CACNB2):c.441T>C (p.Phe147=)]

NM_201596.3(CACNB2):c.441T>C (p.Phe147=)

Gene:
CACNB2:calcium voltage-gated channel auxiliary subunit beta 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
10p12.31
Genomic location:
Preferred name:
NM_201596.3(CACNB2):c.441T>C (p.Phe147=)
HGVS:
  • NC_000010.11:g.18498462T>C
  • NG_016195.1:g.362786T>C
  • NM_000724.4:c.276T>C
  • NM_001167945.2:c.357T>C
  • NM_001330060.2:c.276T>C
  • NM_001410882.1:c.297T>C
  • NM_201570.3:c.297T>C
  • NM_201571.4:c.357T>C
  • NM_201572.4:c.357T>C
  • NM_201590.3:c.279T>C
  • NM_201593.3:c.441T>C
  • NM_201596.3:c.441T>CMANE SELECT
  • NM_201597.3:c.441T>C
  • NP_000715.2:p.Phe92=
  • NP_001161417.1:p.Phe119=
  • NP_001316989.1:p.Phe92=
  • NP_001397811.1:p.Phe99=
  • NP_963864.1:p.Phe99=
  • NP_963865.2:p.Phe119=
  • NP_963866.2:p.Phe119=
  • NP_963884.2:p.Phe93=
  • NP_963887.2:p.Phe147=
  • NP_963890.2:p.Phe147=
  • NP_963891.1:p.Phe147=
  • LRG_381t1:c.441T>C
  • LRG_381t2:c.279T>C
  • LRG_381:g.362786T>C
  • LRG_381p1:p.Phe147=
  • LRG_381p2:p.Phe93=
  • NC_000010.10:g.18787391T>C
Molecular consequence:
  • NM_000724.4:c.276T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001167945.2:c.357T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001330060.2:c.276T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001410882.1:c.297T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201570.3:c.297T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201571.4:c.357T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201572.4:c.357T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201590.3:c.279T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201593.3:c.441T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201596.3:c.441T>C - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_201597.3:c.441T>C - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
Brugada syndrome 4 (BRGDA4)
Identifiers:
MONDO: MONDO:0012743; MedGen: C2678477; Orphanet: 130; OMIM: 611876

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004378731Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely benign
(Jul 15, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Nothing to display

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004378731.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024